透過您的圖書館登入
IP:216.73.216.29
  • 期刊

中醫治療肝癌併新冠後腹瀉納差之病例報告

Hepatocellular Carcinoma combined Post-Covid 19 syndrome Treated with Traditional Chinese Medicine--A Case Report

摘要


54歲男性患者有慢性B型肝炎病史,於2013年被診斷為右側肝臟腫瘤復發合併主肝門靜脈及左肝門靜脈侵犯,2022年10月5日經肝膽腸胃科門診收治住院接受常規標靶免疫治療時,於9月19日確診Covid-19後出現噁心、腹瀉、食慾不振及體重減輕情況,尋求協同治療。其症候為噁心、腹瀉、食慾差、精神疲倦、腹脹、輕微右側腹悶痛、咳嗽與胸悶,舌紅絳,苔白黃厚少津,脈弦滑有力,中醫診斷為癥瘕、鼓脹、癥積,證屬,外邪傷正,肝旺脾虛,溼濁中阻氣滯,給予五苓散、痛瀉藥方,合行氣、芳香化溼藥物加減以補脾瀉肝、利水滲溼、下氣寬中,合併傳統針灸與雷射針灸治療,經過六天治療,腹瀉、納差症狀獲得顯著改善,體重增加1.5公斤,患者於10月15日出院繼續門診追蹤治療。

並列摘要


A 54-year-old male with chronic hepatitis B and Hepatocellular carcinoma combined with covid infection on September 19, 2022 was admitted by Gastroenterology Outpatient Department for regular immunotherapy for hepatocellular carcinoma on October 5, 2022. After admission, the symptoms of nausea, diarrhea, loss of appetite and weight loss were noted and his attending physician consulted Traditional Chinese Medicine for collaborative treatment. During the consultation, the patient's symptoms were nausea, diarrhea, poor appetite, fatigue, abdominal distension, mild abdominal pain on the right side, cough and chest tightness. Red, crimson and thick tongue coating white and yellow with less fluid, stringy, slippery and strong pulse were also noted. The diagnosis of Traditional Chinese Medicine was accumulation of lumps and the syndrome belongs to external pathogenic injury, liver hyperactivity and spleen deficiency, and turbid damp obstructing in middle with qi stagnation. The formula of Wulingsan and Tong Xie Yao Fang was for painful diarrhea, combined with qi-promoting and aromatic dampness-removing medicines to invigorate the spleen, relieve the liver, and diuresis. Diarrhea and anorexia symptoms were significantly improved after six days of treatment, and patient's body weight gained 1.5 kg. The patient was discharged on October 15 to continue outpatient follow-up treatment.

參考文獻


Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A: Hepatocellular carcinoma. Lancet. 2022; 400(10360): 1345-1362.
Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328(25): 1797-801
Bu Y, Jia QA, Ren ZG, Xue TC, Zhang QB, Zhang KZ, Zhang QB, You Y, Tian H, Qin LX, Tang ZY: The herbal compound Songyou Yin (SYY) inhibits hepatocellular carcinoma growth and improves survival in models of chronic fibrosis via paracrine inhibition of activated hepatic stellate cells. Oncotarget. 2015; 6(37): 40068-80.
Aravalli RN, Steer CJ: Immune-Mediated Therapies for Liver Cancer. Genes (Basel). 2017; 8(2): 76.
Lam P, Cheung F, Tan HY, Wang N, Yuen MF, Feng Y: Hepatoprotective Effects of Chinese Medicinal Herbs: A Focus on Anti-Inflammatory and Anti-Oxidative Activities. Int J Mol Sci. 2016; 17(4): 465.

延伸閱讀